Details for Patent: 7,612,058
✉ Email this page to a colleague
Title: | Methods for inhibiting sterol absorption |
Abstract: | The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. |
Inventor(s): | Cho; Wing-Kee Philip (Princeton, NJ) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Filing Date: | Nov 29, 2004 |
Application Number: | 10/998,400 |
Claims: | 1. A method of treating a vascular condition associated with elevated sterol and/or stanol levels, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00003 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00087## 2. The method according to claim 1, wherein the vascular condition is atherosclerosis. 3. A method of treating diabetes in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00004 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00088## 4. A method of treating obesity in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00005 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00089## 5. A method of lowering a plasma sterol concentration of a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00006 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00090## 6. A method of treating a vascular condition associated with elevated sterol and/or stanol levels, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00007 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00091## 7. The method according to claim 6, wherein the vascular condition is atherosclerosis. 8. A method of treating diabetes in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00008 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00092## 9. A method of treating obesity in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00009 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00093## 10. A method of lowering a plasma sterol concentration of a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00010 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00094## |